CoChat
Sign Up
Cited by 129Amyotrophic Lateral Sclerosis ResearchSpinal Cord Injury ResearchPluripotent Stem Cells Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome

Open access
Mazzini, Letizia, Gelati, Maurizio, Profico, Daniela Celeste, Sorarù, Gianni, Ferrari, Daniela, Copetti, Massimiliano, Muzi, Gianmarco, Ricciolini, Claudia, Carletti, Sandro, Giorgi, Cesare, Spera, Cristina, Frondizi, Domenico, Masiero, Stefano, Stecco, Alessandro, Cisari, Carlo, Bersano, Enrica, De Marchi, Fabiola, Sarnelli, Maria Francesca, Querin, Giorgia, Cantello, Roberto, Petruzzelli, Francesco, Maglione, Annamaria, Zalfa, Cristina, Binda, Elena, Visioli, Alberto, Trombetta, Domenico, Torres, Barbara, Bernardini, Laura, Gaiani, Alessandra, Massara, Maurilio, Paolucci, Silvia, Boulis, Nicholas M., Vescovi, Angelo L., on behalf of the ALS-NSCs Trial Study Group·2019·Stem Cells Translational Medicine
DOI 10.1002/sctm.18-0154PMC PMC6708070
Open this paper in CoChat — free accountOpen PDF

Abstract

The main objective of this phase I trial was to assess the feasibility and safety of microtransplanting human neural stem cell (hNSC) lines into the spinal cord of patients with amyotrophic lateral sclerosis (ALS). Eighteen patients with a definite diagnosis of ALS received microinjections of hNSCs into the gray matter tracts of the lumbar or cervical spinal cord. Patients were monitored before and after transplantation by clinical, psychological, neuroradiological, and neurophysiological assessment. For up to 60 months after surgery, none of the patients manifested severe adverse effects or increased disease progression because of the treatment. Eleven patients died, and two underwent tracheotomy as a result of the natural history of the disease. We detected a transitory decrease in progression of ALS Functional Rating Scale Revised, starting within the first month after surgery and up to 4 months after transplantation. Our results show that transplantation of hNSC is a safe procedure that causes no major deleterious effects over the short or long term. This study is the first example of medical transplantation of a highly standardized cell drug product, which can be reproducibly and stably expanded ex vivo, comprising hNSC that are not immortalized, and are derived from the forebrain of the same two donors throughout this entire study as well as across future trials. Our experimental design provides benefits in terms of enhancing both intra- and interstudy reproducibility and homogeneity. Given the potential therapeutic effects of the hNSCs, our observations support undertaking future phase II clinical studies in which increased cell dosages are studied in larger cohorts of patients. Stem Cells Translational Medicine 2019;8:887–897

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sctm.18-0154

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

  1. Brooks, 2000, Amyotroph Lateral Scler Other Motor Neuron Disorder, 293
  2. McNair, 1992, Revised Manual for the Profile of Mood States
  3. O'Boyle, 1993, The Schedule for the Evaluation of Individual Quality of Life (SEIQoL): A Direct Weighting Procedure for Quality of Life Domains (SEIQoL-DW)

Cited by

Sorted by citations

Items 101–129 of 129

Related

See all

Metadata

Authors
Mazzini, L., Gelati, M., Profico, D. C., Sorarù, G., Ferrari, D., Copetti, M., Muzi, G., Ricciolini, C., Carletti, S., Giorgi, C., Spera, C., Frondizi, D., Masiero, S., Stecco, A., Cisari, C., Bersano, E., De Marchi, F., Sarnelli, M. F., Querin, G., Cantello, R., Petruzzelli, F., Maglione, A., Zalfa, C., Binda, E., Visioli, A., Trombetta, D., Torres, B., Bernardini, L., Gaiani, A., Massara, M., Paolucci, S., Boulis, N. M., Vescovi, A. L., & on behalf of the ALS-NSCs Trial Study Group
Affiliations
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • Casa Sollievo della Sofferenza (IT)
  • d Department of Neuroscience University of Padua, Padua, Italy
  • University of Milano-Bicocca (IT)
  • Azienda Ospedaliera S.Maria (IT)
  • University of Padua (IT)
  • Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
  • a Eastern Piedmont University, “Maggiore della Carità” Hospital Dipartimento di Neurologia, Novara
  • l StemGen SpA, Milan, Italy
  • n Fondazione IRCCS Casa Sollievo della Sofferenza Cytogenetics Unit, San Giovanni Rotondo, Foggia, Italy
  • Emory University (US)
Corresponding author
  • Mazzini, Letizia
  • Vescovi, Angelo L.
ORCID
Venue
Stem Cells Translational Medicine
Publisher
Oxford University Press (OUP)
Published
2019-05-18
Volume
8
Issue
9
Pages
887-897
ISSN
  • 2157-6564 (ISSN-L)
  • 2157-6580
DOI
10.1002/sctm.18-0154
PMC
PMC6708070
OpenAlex
W2945776234
Cited by
128
References
42
Citations by year
2026: 10 · 2025: 21 · 2024: 19 · 2023: 23 · 2022: 14 · 2021: 20 · 2020: 17 · 2019: 3
FWCI
9.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cells Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
  • HAL (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Clinical Neurology › Spinal Cord Injury Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
Keywords
amyotrophic lateral sclerosis, neural stem cells, cell therapy safety, disease progression, ALSFRS-R, long-term outcomes, ex vivo cell expansion
MeSH terms
Adult, Aged, Amyotrophic Lateral Sclerosis, Brain, Female, Glial Fibrillary Acidic Protein, Humans, Injections, Spinal, Magnetic Resonance Imaging, Male, Middle Aged, Pain, Pilot Projects, Spinal Cord, Treatment Outcome, Brain-Derived Neurotrophic Factor, Stem Cell Transplantation, Vascular Endothelial Growth Factor A, Young Adult, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review